Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
202.00
Value Traded
0.04
Short % Float
2.4%
0%Week
0%1 Month
0%3 Month
0%6 Month
0%5 Year
-95.8%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
10.54 M
EPS (TTM)
-4.11
P/E Ratio
-
Ent. Value
6.34 M
Total Shares
4.47 M
Float Shares
3.33 M
Insiders
6.53%
Institutions
1.41%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
LIPO Catalyst Timeline
Dated clinical, regulatory and corporate events for Lipella Pharmaceuticals Inc.
Past FDA Catalysts and PDUFA Decisions
How LIPO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | LP-310 (liposomal-tacrolimus oral rinse formulation) | Phase 2a data readout | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LP-10 Small moleculeCompletedNCT03129126 | Hemorrhagic Cystitis | Phase 2 | COMPLETED | 13 | Sep 29, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every LIPO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| LP-10 | oral lichen planus | Phase 2a | 2025-09-18 | safety profile: met its primary safety endpoint; efficacy outcomes: statistically significant improvements across all efficacy measures at the 4-week timepoint; dose groups: All three dose groups (0.25 mg, 0.5 mg, and 1.0 mg) demonstrated statistically significant improvements at Week 4 (all p<0.05); IGA: showed clear reductions in ulceration and erythema scoresRead More | Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen PlanusRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kaufman Jonathan HDirector, Officer (See remarks below.), 10% Owner | Buy | 10,000 898,849 held | $0.76 | 05/14/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in LIPO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LIPO for Q2 2026. | ||||
Ownership Trends
LIPO Short Interest
Shares sold short, counted twice a month.
2.4%
Short % of Float
of tradable shares sold short
1.2K
Shares Sold Short
0.0% vs prior count
-
Days to Cover
trading days of normal volume to buy every short share back
755
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LIPO ranks across every disease it competes in
Competitive Position is a premium feature
See how LIPO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLIPO News
About Lipella Pharmaceuticals Inc.
Headquarters7800 Susquehanna St.
Founded19-12-2022
BIOPHARMAWATCH ELITE PLUS
Trade the next LIPO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime